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Abstract
Significant progress has been made in characterizing broadly neutralizing antibodies
against the HIV envelope glycoprotein Env, but an effective vaccine has proven elusive.
Vaccine development would be facilitated if common features of early founder virus required
for transmission could be identified. Here we employ a combination of bioinformatic and
operations research methods to determine the most prevalent features that distinguish 78
subtype B and 55 subtype C founder Env sequences from an equal number of chronic
sequences. There were a number of equivalent optimal networks (based on the fewest
covarying amino acid (AA) pairs or a measure of maximal covariance) that separated foun-
ders from chronics: 13 pairs for subtype B and 75 for subtype C. Every subtype B optimal
solution contained the founder pairs 178–346 Asn-Val, 232–236 Thr-Ser, 240–340 Lys-Lys,
279–315 Asp-Lys, 291–792 Ala-Ile, 322–347 Asp-Thr, 535–620 Leu-Asp, 742–837 Arg-
Phe, and 750–836 Asp-Ile; the most common optimal pairs for subtype C were 644–781
Lys-Ala (74 of 75 networks), 133–287 Ala-Gln (73/75) and 307–337 Ile-Gln (73/75). No pair
was present in all optimal subtype C solutions highlighting the difficulty in targeting transmis-
sion with a single vaccine strain. Relative to the size of its domain (0.35% of Env), the α4β7
binding site occurred most frequently among optimal pairs, especially for subtype C: 4.2% of
optimal pairs (1.2% for subtype B). Early sequences from 5 subtype B pre-seroconverters
each exhibited at least one clone containing an optimal feature 553–624 (Ser-Asn), 724–
747 (Arg-Arg), or 46–293 (Arg-Glu).
Introduction
There has been a significant global effort to develop an effective vaccine for HIV. Vaccine trials
to date have shown limited efficacy but what success there has been was associated with the
ability of the vaccine to stimulate HIV envelope glycoprotein (Env) antibodies [1, 2]. Hence
future vaccine candidates will most likely include a component that elicits antibodies specific
to targets on Env. However, HIV-1 has an extremely high rate of sequence evolution and
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strains in different communities form distinct subtypes [3]; high strain diversity exists between
individuals and even within any one patient [4]. The challenge for vaccines stimulating anti-
bodies to Env is to target rare common epitopes between viral strains, and ideally between sub-
types [1]. These targets should be representative of early founder virus clones that emerge
through the strain-selecting bottleneck of transmission [5].
A newly infecting clone quickly undergoes sequence evolution impacted by a developing
immune response, as assessed by differences between founder and chronic viral sequences [5–
11]. Importantly for vaccines aiming to prevent transmission, HIV infection generally results
from a single transmitted virus strain [5, 8], indicating the potential benefits of identifying key
transmission-related features. Envelope features are of particular relevance as it is the only
HIV protein exposed on the outer surface of an infectious particle, also making it the target for
neutralising antibodies [12]. Despite extreme Env sequence diversity, all strains must preserve
the functional properties of CD4 receptor binding and binding to chemokine coreceptors such
as CCR5 and CXCR4 that facilitate entry. Almost all founder virus uses the CCR5 coreceptor
[11], a trait mostly encoded in the V3 loop of Env [13]. Other HIV Env functional domains
include motifs allowing interaction with cell adhesion and trafficking receptors, like the Integ-
rin α4β7 glycoprotein. This glycoprotein acts as a gut-homing receptor for lymphocytes, target-
ing them to the extensive gut associated lymphatic tissues (GALT) that are important sites for
explosive viral expansion in the early phase of infection [14–16].
Envelope is the target for broadly neutralizing antibodies (bNAb), and several conserved
tertiary structures on Env have been identified as vulnerable sites for bNAb binding [17, 18]. It
is unclear whether important new conformational targets for bNAb might be selected during
transmission. Understanding what Env features are unique to the transmitted virus but which
evolve to escape selection under immune pressure, may point to possible vaccine targets
[11, 19].
One approach to identifying vaccine targets is to determine individual amino acids (AA)
that differ significantly between chronic and founder sequences among the 857 positions of
the Env glycoprotein gp160 [7]. This glycoprotein is cleaved to form the 511 AA CD4 binding
subunit gp120, and the 346 AA gp41 that is required for fusion of the virus with the cell mem-
brane. This non-covalently bound heterodimer self-associates into trimers that form the func-
tional Env spike on the viral surface that determines viral tropism. By chance there will be
many differences in these sequences, given the large variability in some regions of Env. Func-
tionally related sites can also be compared between these groups, as well as the number of gly-
cosylation sites [7, 9]. This direct comparison of individual positions or known functional sites
has proven useful but is limited. How AA and regions within the linear Env genetic sequence
determine function is related to their positions in the complex 3-dimensional Env trimer
structure [20–22], and determining the interplay between AA in this structure is not straight-
forward. Any susceptibility in the transmission virus will result in the Env sequence evolving
in a series of compensatory escape mutations, so that the trimer structure is altered in order to
avoid or minimise the effectiveness of the developing immune response [11, 12]. This collec-
tion of escape mutations need not be contiguous in the sequence but will form a biologically
related network of positions in Env.
One way of identifying biologically related areas within a highly structured protein involves
calculating positions on a set of AA sequences that covary. Pairs of positions are said to covary
if the AA combinations observed at these positions are sufficiently different from random
combinations. For example if in 16 Env sequences at positions 223 and 432 there were 8 Phe-
Lys pairs and 8 Tyr-Arg pairs then positions 223 and 432 would covary since these observed
pairs are sufficiently different to the random combinations of 4 Phe-Lys, 4 Phe-Arg, 4 Tyr-Lys
and 4 Tyr-Arg pairs. It would also suggest that these positions are linked in some functional
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manner. If a virus is to evolve under immune pressure, then a single mutation is usually insuf-
ficient and a number of compensatory, fitness-restoring mutations at other positions are
required [23, 24]. Each of these compensatory mutations results in a covarying pair and the
entire set of mutations results in a network of covarying pairs [25]. Analysing sequences using
the covariance between amino acid positions is a useful approach in a variety of applications
[26–29]. In the case of Env, amino acid sequence networks of covarying pairs contain possible
vaccine targets, especially if we can identify those combinations that are transmission signa-
tures present in founder sequences but absent in chronic sequences. Here we follow the
approach developed in Murray et al. [30], where optimisation methods were used in combina-
tion with covariance calculations to determine the most prominent features that differentiate
one hepatitis C virus group from another. We apply these methods to sets of founder and
chronic HIV subtype B and subtype C Env sequences, with the aim of identifying features that
distinguish founder from chronic virus and that represent possible vaccine targets.
Results
As described previously [9], HIV Env sequences for 133 transmission strain cases (78 subtype
B, 55 subtype C) were obtained from Keele et al. and Abrahams et al. [5, 8]. Subtype C is the
most common virus in Africa whereas subtype B is prevalent in developed countries such as
Australia and the US. These founder sequences represent the inferred single clones that gave
rise to productive infection in these individuals [5, 8]. A comparison group of 133 HIV Env
sequences were derived from the plasma of individuals with chronic infection, obtained from
the Los Alamos National Laboratory (LANL) HIV sequence database. Each randomly selected
control sequence was investigated and submitted to rigorous exclusion criteria. Controls
were frequency-matched on HIV-1 subtype and geographical location (consistent with the
approach of Gnanakaran et al. [7]), with 78 subtype B chronic sequences selected from USA/
Trinidad and Tobago and 55 subtype C sequences selected from South Africa/Malawi.
The sequences were aligned and numbered relative to the HXB2 reference strain [31]. The
phylogenetic trees for these subtypes and how the Founder and Chronic sequences distribute
are shown in Fig 1.
After alignment of the approximately 857 long AA Env sequences, covarying pairs were cal-
culated as previously described [25, 30], to indicate AA positions in Env that are possibly con-
nected through function, where a change in one position is likely to also result in a change in
another position. In this study we analyse both subtype B and C viruses, hence it was necessary
to perform the covariance calculations separately for each subtype. There were 2,495 covarying
pairs over the 156 subtype B sequences and 3,021 subtype C covarying pairs over the 110 sub-
type C sequences. The maximum covariance values were similar for each of the subtypes, 14.0
for subtype B and 14.6 for subtype C, however there were more covarying pairs for subtype C
that were close to this maximum value (Fig 2). The slightly higher covariance among subtype
C, despite fewer sequences, tends to reflect the more clustered phylogenetic tree. This has been
observed previously with differences in covariance between 1a and 1b HCV sequences mirror-
ing the clustering of these sequences [30].
Covarying AA contain possible targets for a vaccine-stimulated response since they are not
totally conserved, but are not so variable as to represent random changes. We mapped regions
that were conserved, covarying and variable in Env over both subtypes (Fig 2). For subtype C,
highly covarying pairs clustered in the signal, V2, and C5 regions of gp120 and in gp41. The
pair with the highest covariance was 474–476, while the positions that appeared most were 192
(22 times), 476 (12), 27 (12), 11 (11), 706 (11), 388 (10), 595 (10). Covarying pairs were inci-
dent (one of the positions within the pair) 11 times to the α4β7 binding site (positions 179 to
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181). For subtype B the pair with the highest covariance was 230–232, connecting within an N-
linked glycosylation site (NXS/T at positions 230, 231, 232), and the other highly covarying
pairs tended to be in close proximity as well. One of these covarying pairs (181–693), was also
incident to the α4β7 binding site.
Optimal networks
The covarying pairs determine components within the sequences that vary but not in a ran-
dom fashion. However as depicted in Fig 2, there can be many of these. Our aim was to deter-
mine what is special in founder viruses. We define a separating pair as a covarying pair of
Fig 1. Unrooted phylogenetic trees for the subtype B and C HIV Env sequences. Founder sequences are shown with red dashed
branches, while chronic sequences are denoted by blue branches.
doi:10.1371/journal.pone.0171572.g001
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positions and its AA combination, where at that pair of positions, the AA combination is
exhibited by some sequence in the founder group but by none in the chronic group. Hence we
search among separating pairs to determine signatures of founder virus that are not expressed
by any chronic virus in our samples. To determine those that are most pertinent to characteris-
ing founder virus we calculated optimal collections of separating pairs. Optimality was based
on requiring the fewest pairs to separate these groups or that tended to maximise covariance
(Methods). Separation of Founders from Chronics becomes more difficult as fewer pairs are
used. Hence the solution with the fewest pairs will likely contain stronger predictors of what
differs between these groups. This is similar in essence to identifying AA and their positions
where comparisons between the groups gives the lowest p or q values [7]. Initially a single opti-
mal network was identified for each of the subtype/covariance group combinations (covari-
ance over all, founder, or chronic sequences), and objective function type (fewest pairs or
optimising covariance). Hence, twelve optimal networks were identified and used in this part
of the analysis.
Optimization enforces two limitations on this problem. Firstly it can only be applied to a
single alignment rather than a bootstrapped collection of alignments. To compensate for this
limitation we only included covariance calculated over positions that contained at most 10%
gaps. This had the effect of excluding some of the more variable regions around indels. Sec-
ondly this binary integer programming problem belongs to the class of Non-Polynomially
(NP) Hard problems that are characterised by small increases in problem size (here this is
related to the number of covarying pairs) resulting in large increases in computational time.
Fig 2. Conserved and covarying regions for subtypes B and C Env. Regions are coloured as conserved across both subtypes (black), conserved
within each subtype (dark blue), conserved except for a maximum of 2 individuals in that subtype (light blue), and covarying (magenta). Those covarying
pairs with at least 20% of the maximum covariance value for subtype C, and 12.5% for subtype B, are connected with magenta lines. The different levels of
covariance were determined to include approximately the same numbers of covarying pairs in each case: 78 for subtype B and 79 for subtype C. The
signal, α4β7 binding site, constant (C1-C6) and variable (V1-V5) regions within gp120, and the gp41 domain are mapped onto the Env sequence.
doi:10.1371/journal.pone.0171572.g002
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Partly for this reason we limited the size of the problem by only including pairs with a covari-
ance value of at least 0.5, leading to the 2,495 covarying pairs for subtype B described above.
Including pairs with a covariance of 0.1 would have led to an almost 10-fold increase in the
number of pairs (21,937 for subtype B). The difficulty of solving these problems with lower
covariance cut-off is highlighted by the related connected optimal network problem being com-
putationally intractable in reasonable time even with the 0.5 cut-off [32]. Nevertheless to
address sensitivity to this assumption, we also investigate in a later section a slightly simpler
problem but with no covariance cut-off.
The optimal networks, determining features of Founder sequences that separate them from
Chronic sequences, required between 13 and 15 AA pairs for subtype B (S1 Table). The fewer
subtype C sequences required between 11 and 13 AA pairs to separate all Founder sequences
from Chronic sequences. Some of the pairs within the optimal networks appeared multiple
times for the 6 optimization problems in each subtype/group combination (3 minimizing the
number of pairs, and 3 optimizing a measure of total covariance). For subtype B the pairs 278–
620 (Ser Asp), and 750–836 (Asp Ile) each appeared 4 times, while for subtype C the most
frequently appearing pairs (3 times each) were 170–192 (His Arg) and 588–662 (Arg Ala)
(Table 1).
Several single positions within these Env sequences appeared frequently in optimal net-
works (Table 2). Positions 836 and 620 for subtype B, and positions 192 and 346 for subtype C
were the most frequently appearing single positions. Position 346 for subtype C was also proxi-
mal to position 347 appearing 6 times for subtype B in the constant C3 region of gp120. The
next most frequently appearing proximal positions were 178 for subtype B and 179 for subtype
C that were within or next to the α4β7 binding site.
Table 1. Pairs observed multiple times (frequency f) in optimal networks for each subtype. The num-
ber of individuals exhibiting each AA combination is denoted by n.
B C
AA positions f n AA AA positions f n AA
278 620 4 15 SD 170 192 3 5 HR
750 836 4 14 DI 588 662 3 6 RA
230 232 3 3 DQ 7 10 2 7 QY
232 236 3 10 TS 161 192 2 4 AI
535 620 3 9 LD 179 674 2 4 PN
151 178 2 3 GN 192 343 2 5 IQ
240 340 2 8 KK 295 334 2 7 EN
283 621 2 3 IE 344 346 2 7 KG
291 792 2 4 AI 352 379 2 8 YG
293 337 2 5, 3 VD, QK 393 727 2 4 DP
319 836 2 6 TT 417 770 2 8 QQ
336 845 2 9 ET 448 727 2 6 SL
347 543 2 10 TL 721 727 2 7 IL
440 620 2 5 KD
624 747 2 8 ER
724 758 2 10 RD
724 837 2 11 RF
747 758 2 3 QD
818 840 2 11 IF
doi:10.1371/journal.pone.0171572.t001
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Multiple optimal solutions for each subtype/group combination
The optimization procedure above determines an optimal solution but these are not unique.
For example, the first row of S1 Table shows that an optimal solution for the problem where
we minimize the number of pairs, contains 13 pairs for subtype B and 11 pairs for subtype C,
Table 2. Single AA in optimal networks determined on Founders, which appear at least 2 times (frequency f). The region of Env is denoted ahead of
a decimal point, and any recognised motif after the decimal.
B C
position domain f position domain f
836 41CT.LLP-1 α helix 10 192 V2 8
620 41ED.HR2 9 346 C3 7
232 C2.NGS 6 727 41CT.KenEpi 6
347 C3 6 624 41ED 5
336 C3 5 7 Sig 4
535 41ED.aHR1 5 161 V2 4
724 41CT 5 179 V2.α4β7 4
747 41CT 5 295 V3.NGS(2G12) 4
750 41CT.NGS 5 588 41ED.HR1 4
178 V2.α4β7 4 10 Sig 3
230 C2 4 170 V2 3
278 C2 4 344 C3 3
291 C2.NGS 4 350 C3 3
621 41ED 4 393 V4 3
624 41ED 4 662 41ED 3
758 41CT 4 674 41ED 3
92 C1.120•41 3 721 41CT 3
151 V1 3 832 41CT.LLP-1 α helix 3
236 C2.NGS 3 27 Sig 2
240 C2.NGS 3 29 Sig 2
283 C2 3 172 V2 2
293 C2 3 181 V2.α4β7 2
319 V3.R5/X4bs 3 334 C3 2
354 C3 3 337 C3 2
543 41ED 3 343 C3 2
837 41CT.LLP-1 α helix 3 352 C3 2
24 Sig 2 379 C3 2
181 V2.α4β7 2 417 C4 2
335 C3 2 440 C4 2
337 C3 2 448 C4 2
340 C2.NGS 2 496 C5 2
440 C4 2 619 41ED 2
444 C4 2 621 41ED 2
553 41ED 2 770 41CT.LLP-2 α helix 2
640 41ED 2 833 41CT.LLP-1 α helix 2
792 41CT.LLP-3 α helix 2
818 41CT 2
833 41CT.LLP-1 α helix 2
840 41CT.LLP-1 α helix 2
845 41CT.LLP-1 α helix 2
doi:10.1371/journal.pone.0171572.t002
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when covariance is calculated over all sequences within each subtype. However a total of 13
different optimal networks that each differ by at least one AA pair for subtype B can be identi-
fied for this particular problem (Table 3). Similarly, for the subtype C sequences there are 75
optimal solutions. However these optimal solutions share several features. For subtype B there
are 9 pairs that are present in each of the 13 optimal solutions, indicating possibly susceptible
Table 3. The pairs that are observed in a given number of optimal solutions for subtypes B and C.
Listed for each of the optimal separating pairs are the covarying positions, the amino acids for the sequences
in the Founder separating pairs, and then the Env motifs for each of these positions. The optimization problem
was solved using objective i) (minimizing the number of pairs) on a covariance network constructed using all
sequences in each subtype.
Subtype B (13 optimal solutions)
Observed in 13 solutions
178–346 Asn Val V2.α4β7[33] C3
232–236 Thr Ser C2.NGS C2.NGS
240–340 Lys Lys C2.aNGS C3
279–315 Asp Lys C2.CD4bs[34, 35] V3.R5/X4bs[36]
291–792 Ala Ile C2.NGS 41CT.LLP-3 α helix[37–39]
322–347 Asp Thr V3.R5/X4bs[36] C3
535–620 Leu Asp 41ED.aHR1 41ED.HR2
742–837 Arg Phe 41CT.KenEpi[40] 41CT.LLP-1 α helix[37–39]
750–836 Asp Ile 41CT.NGS 41CT.LLP-1 α helix[37–39]
Observed in 11 solutions
92–346 Lys Val C1.120•41 C3
Observed in 10 solutions
588–836 Lys Thr 41ED.HR1 41CT.LLP-1 α helix[37–39]
Subtype C (75 optimal solutions)
Observed in 74 solutions
644–781 Lys Ala 41ED.HR2 41CT.LLP-2 α helix[37–39]
Observed in 73 solutions
133–287 Ala Gln V1 hvr C2.nCD4bs[34, 35]
307–337 Ile Gln V3.R5/X4bs[36] C3
Observed in 72 solutions
10–346 Tyr Gly Sig C3
132–841 Ser Leu V1 hvr 41CT.LLP-1 α helix[37–39]
295–322 Glu Asp V3.NGS(2G12)[41] V3.R5/X4bs[36]
721–727 Ile Leu 41CT 41CT.KenEpi [40]
778–779 Val Val 41CT.LLP-2 α helix[37–39] 41CT.LLP-2 α helix[37–39]
779–833 Val Val 41CT.LLP-2 α helix[37–39] 41CT.LLP-1 α helix[37–39]
The region of Env is denoted ahead of a decimal point, and any recognised motif after the decimal. The
covarying pairs are separated by—a dash. Sig = Env signal peptide; C2 = constant domain 2; C3 = constant
domain 3, V1 = variable domain 1, V2 = variable domain 2, V3 = variable domain 3, 41ED = gp41
ectodomain external to membrane; 41CT = gp41 cytoplasmic tail internal to the membrane; α4β7 = alpha-
4-beta-7 integrin binding site; NGS = N-linked glycosylation site; aNGS = amino acid adjacent to NGS;
nNGS = near to NGS; C3 = constant region 3.; CDbs = residues mapped to contacting at the CD4 binding
site; R5/X4bs = residues mapped to contact R5 or X4 coreceptor; V1hvr = Variable region 1 hyper variable
region; HR1 = helix region 1; aHR1 = adjacent to HR1; HR2 = helix region 2 that contains T20 drug site;
120•41 contact residues between gp120 and gp41; KenEpi = Kennedy Epitope–highly immunogenic epitope
[40]; LLP-1 helix = lentiviral lytic peptide– 1 alpha helix; LLP-2 helix = lentiviral lytic peptide– 2 alpha helix;
LLP-3 helix = lentiviral lytic peptide– 3 alpha helix.
doi:10.1371/journal.pone.0171572.t003
Differentiating founder and chronic HIV
PLOS ONE | DOI:10.1371/journal.pone.0171572 February 10, 2017 8 / 19
immune-evasion pathways. For subtype C, 644–781 (Lys Ala) is present in 74 solutions, while
2 pairs appear in 73 solutions, and 6 pairs in 72 solutions. It is interesting to note that there are
no pairs for subtype C that are present in all 75 optimal solutions, suggesting a greater number
of pathways by which this virus evolves and possibly making it a more difficult vaccine target.
Optimal networks with no covariance restriction
By restricting pairs to those with a covariance value of 0.5 or higher, we attempted to deter-
mine functionally relevant positions. However this excluded many other possibilities. Allowing
all pairs to be considered in separating Founder from Chronics, increased the number of pairs
more than 50-fold, making the calculation of optimal networks with criterion (ii) that incorpo-
rated the covariance value computationally impractical. However we could still determine
optimal networks that achieved separation of Founders from Chronics with the fewest number
of pairs. The optimal subtype B network contained 12 separating pairs: 46–293 (Arg Glu), 84–
333 (Val Val), 269–767 (Asp Lys), 278–620 (Ser Asp), 291–758 (Ala Val), 293–375 (Val Thr),
336–535 (Glu Met), 345–842 (Ile Asn), 535–624 (Lys Asp), 553–624 (Ser Asn), 724–747 (Arg
Arg), 750–836 (Asp Ile). Despite including many more pairs, this optimal network contained
only one or two fewer optimal pairs than with the above S value cut-off. Moreover 750–836
(Asp Ile) appeared in all multiple optimal solutions (Table 3).
The subtype C optimal solution without covariance restriction consisted of 9 pairs: 9–515
(Asn Met), 12–350 (Gln Ser), 166–352 (Lys His), 330–620 (Tyr Thr), 352–379 (Tyr Gln), 448–
821 (Ser Ala), 565–588 (Met Arg), 640–778 (Asn Val), 833–837 (Leu Cys).
Occurrence of optimal pairs in virus cloned prior to seroconversion
The above calculations determined aspects of founder sequences that might be targeted by vac-
cines. Given the large number of covarying pairs determined in this way, it is unlikely that all
of these pairs would be robust predictors of susceptibility. To test this we sequenced subtype B
Env virus from 5 individuals who were newly infected (Methods). The optimal pairs (for all
subtype B solutions in S1 Table) showed little overlap with the clones derived from these pre-
seroconverters (Table 4). Part of this limitation was due to the cloning process only including
positions 44 to 752. Three of the five individuals and 5 of the 12 clones exhibited some of the
optimal pairs but these were limited to: 343–621 (Gln Asp) and 354–636 (Pro Asp) for one
clone; 553–624 (Ser Asn) for 2 individuals; 624–747 (Glu Arg) for 2 individuals, and 724–747
(Arg Arg) for one individual.
The two pairs 553–624 (Ser Asn) and 724–747 (Arg Arg) were also in the optimal network
determined for subtype B when there was no covariance restriction. After including the 46–
Table 4. Comparison of optimal Founder pairs with the AA combinations appearing for 5 subtype B pre-seroconverters with each of the clones
sequenced.
Founder pairs Env motifs connected Patient: PSC35 PSC89 PSC24 PSC73 PSC182
Clone: 5 10 51 948 955 911 912 913 914 915 928 949
343–621 QD aNGS–aHR2 DD HE QE DD ED QE QD EY IE QE HQ KQ
354–636 PD aNGS -HR2 PS PS PS PN PS PN PD PS PS PN NS GN
553–624 SN HR1- NGS SN SD S- SE SD NE SD SG SN SD SG NN
624–747 ER NGS—aNGS NR DR -R ER DR ER DR GR NR DR GR NR
724–747 RR KenEpi- aNGS PR PR PR RR PR PR PR PR PR PR QR PR
46–293 RE RR RQ RE KE KE RK RK KE KE KA RE KE
doi:10.1371/journal.pone.0171572.t004
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293 (Arg Glu) optimal pair, these three features were exhibited by at least one clone from each
seroconverter (Table 4).
Discussion
By searching over covarying pairs that exhibit covariance above a minimal background level,
we are attempting to determine aspects of Env that exhibit some change, and hence are likely
to reflect, and to be susceptible to, an evolving immune response. Optimal pairs, selected either
by being part of a network with the fewest pairs, or maximizing a measure of covariance, in
some sense represent fundamental aspects of what separates Founder from Chronic virus,
since separation cannot be achieved using fewer pairs or with a higher measure of covariance.
This is analogous to determining AA with the lowest p or q values in a comparison at individ-
ual positions of Env [7]. As with these statistically significant AA, the optimal pairs may indi-
cate components within transmitted viruses that determine selection at the transmission
bottleneck and that can be targeted by bNAbs. Although there are a large number of different
optimal pairs when collected over all problems (60 subtype B and 54 subtype C, determined
from the unique pairs contained within S1 Table), these are not randomly distributed over
Env (Fig 3). The majority are incident to gp41 (54 and 36 pairs respectively have at least one
position in gp41), and occur at regions related to viral fusion and at AA internal to the mem-
brane involved in virion structure and intracellular signalling. There are 20 and 22 optimal
pairs respectively contained entirely within gp120 and that are incident to the C3 region,
which supports the view that these calculations are not entirely driven by the variable regions.
While the next highest region with incident pairs in subtype B is the C2 region (19 pairs) this
was not frequent for subtype C (5 pairs) which instead had high incidence in V2 (19 pairs, 7
pairs for subtype B). Several identified covarying founder virus sites beyond 665 exist within or
beneath the membrane layer and would not directly bind antibody.
The gut-homing α4β7 integrin has been implicated in higher susceptibility to HIV infection
[42] and α4β7 high CD4+ T cells have been suggested as preferential targets in mucosal trans-
mission especially for subtype C [15]. The viral α4β7 binding site is located within V2 at posi-
tions 179 to 181. Despite only covering 3 of the 857 AA in Env, optimal pairs incident to this
domain were particularly prevalent but especially so for subtype C: 4.2% of optimal pairs (S1
Table) relative to 0.35% of Env and a ‘prevalence ratio’ of 11.9 (4.2%/0.35%). Of interest is that
several α4β7 binding site optimal pairs were also incident to the external fusion or membrane
internal domains of Env gp41. While structural connections between V2 and the gp41 fusion
domains can be envisioned from the crystal and cryo-EM structures of Env gp160 [20, 22],
these are not anticipated across the membrane, and suggest a functional connection, possibly
in cell-cell viral transfer. The remainder of V2 was also prevalent in these optimal pairs for
subtype C with a prevalence ratio of 4.6. The α4β7 binding site was less likely to be represented
in this analysis for subtype B with a prevalence ratio of 3.3, but still higher than the other
domains. However these results are in contrast to findings that blocking binding to α4β7 had
little impact on infection by founder subtype C virus [43], or that HIV Env is in general a poor
ligand for this integrin [44]. Nevertheless monoclonal antibodies that targeted α4β7 integrin-
expressing CD4+ T cells protected rhesus macaques from SIV infection, possibly suggesting a
large role played by early virus in binding to these cells [45], although it is unclear whether this
effect was through altered Env binding and entry, or through altered gut mucosal trafficking.
The subtype C α4β7 pairs were also incident to the domains: signal (1), V2 (1), C3 (2) and gp41
(2). Of note is that the pairs between α4β7 and C3, 181–346 (Val Gln) and 181–364 (Ile Ala),
are incident to N-linked glycosylation sites (339–341 or 344–346, 362–364). Glycosylation sites
in C3 have been observed to affect α4β7 reactivity [15].
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AA within gp41 or the α2 helix in C3 (positions 335 to 353), tended to be central to the net-
works of all optimal pairs for each subtype (Fig 3B), exhibiting the greatest node degrees
within those networks. In particular the C3 α2 helix positions formed a strongly connected
subnetwork for subtype C that also included V2 and α4β7 positions, suggesting these Founder
characteristics evolved under immune pressure in a related manner. This is consistent with
observations of the staged development of antibodies targeting the α2 helix of C3 followed by
those targeting V1-V2 for subtype C [46].
Fig 3. The collection of optimal pairs displayed relative to the domains of Env. A) over a linear representation and B) as networks.
doi:10.1371/journal.pone.0171572.g003
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We identified all optimal solutions relative to the problem of minimizing the number of
pairs with covariance over all sequences, there being many more for subtype C than for sub-
type B (Table 3) possibly related to the higher covariance network exhibited by subtype C (Fig
2) and perhaps reflecting a more diverse pathway of evolution for this genotype. Every subtype
B optimal solution contained a core set of 9 covarying pairs some of which have been identified
through their interactions with bNAbs. Glycans at positions 234 and 276 are essential for the
reactivity of bNAb 8ANC195 [18], where these would be impacted by linked mutations at
nearby sites in the optimal pairs 232–236 and 279–315, that lie at the gp120-gp41 ectodomain
structural interface [20, 22, 47]. Mutations at positions 89, 90, 227, 232 and 243 also dimin-
ished neutralization by bNAb 35O22 [48]. Ten of the 39 founder sequences contained the
232–236 Thr Ser combination, while none of the chronic sequences displayed this feature,
revealing potential differences in N-linked glycosylation that may optimise the viral entry
functions involving the gp120-gp41 interface, but expose a neutralisation sensitive epitope.
As may be expected by the much larger number of optimal solutions for subtype C, there
were no pairs that were common to all solutions. This would suggest that there may be no sin-
gle Env target that will be effective in blocking transmission to an individual in a community
where subtype C is prevalent. Investigation of glycans for an elite subtype C neutralizer showed
N611D and N637K as well as E647A had the greatest effect on neutralization which may be rel-
evant to the 644–781 pair appearing in 74/75 optimal solutions [49]. That the covarying AA lie
beneath the membrane and are shielded from antibody access, raises the possibility of either
structural alterations across the membrane, or effects on cell-cell transmission involving intra-
cellular molecular interactions. One of the glycosylation sites that varied across subtype C
virus commenced at position 133 [50], part of the optimal pair in 73 of 75 optimal solutions.
Positions on the α2 helix of gp120: 236, 305, 332, 335, 336, 337, 343, 350 and 393 are strongly
selected in subtype C for resistance to NAb [51], which may be relevant to the appearance in
multiple optimal solutions of 10–346 Tyr Gly (72/75) and 307–337 Ile Gln (73/74).
Testing whether these optimal subtype B Founder pairs were also represented in early Env
sequences from 5 pre-seroconverters showed little overlap: only 2 pairs connecting C3 to gp41,
and three within gp41 with 2 of these involving gp41 sequence inside the membrane (Table 4).
However one strength of this analysis is that the pairs that did overlap with the seroconverter
sequences were not contained in any of the 78 Chronic sequences. Only positions 44 to 752 of
Env were sequenced in the cloning process which therefore omitted comparison with some of
the optimal pairs. These pre-seroconverter clones may also be variants from the virus that
established the infections approximately 20 days earlier. Effects on cell signalling or cell-cell
transmission may have promoted the identification of AA located beneath the membrane.
Nevertheless identified pairs incident to glycosylation sites were most likely to play a role with
these occurring in the pre-seroconverters at or near positions 354 in C3 and 624 in gp41. A
comparison of the seroconverter sequences with the 12 optimal pairs determined for subtype
B with no covariance restriction revealed 3 features that were exhibited by at least one clone in
each individual: 553–624 (Ser Asn), 724–747 (Arg Arg) (these two were identified in the above
analysis) and 46–293 (Arg Glu).
The optimization and comparison calculations determining differences between Founders
and Chronics can only be performed on a single alignment. Given the high degree of variabil-
ity and the presence of indels in these sequences there will be a number of possible alignments
with differences occurring mainly at, or adjacent to, gaps in the alignment. Partly because of
this we omitted positions where more than 10% of sequences contained gaps or were uncer-
tain. Including these positions leads to optimal separating networks more highly incident to
indels (data not shown) and as such less likely to be robust targets for vaccine stimulated anti-
bodies. Omitting positions that were predominantly gaps meant that we were less able to
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investigate differences in length of some Env regions between Founders from Chronics as pre-
viously observed by us and others [9, 52]. However the number of positions omitted were not
markedly different between Founders vs Chronics—for subtype B there were 26 positions in
the Founder sequences and not in Chronics consisting entirely of gaps and 18 positions in
Chronics but not in Founders (20 vs 17 respectively for subtype C). Dropping positions also
excluded 10 of the 31 HXB2 glycosylation sites so that our analysis will not be able to use
changes in their number as a factor, but which we had previously analysed [9].
A further limitation of our approach is that these sequences were not matched for factors
apart from subtype and geographical region. Matching Founders and Chronics by gender,
transmission mode, etc., would assist in removing extraneous components that confound sep-
aration due to vaccine-relevant factors, but it would reduce the power of the analysis and the
generality of the results. Our general approach of searching among covarying positions, also
assumes that mutation away from the transmitted virus occurs along a few pathways in
response to immune pressure and that then induce covariance. This is generally true for the
mutational pathways within HIV resulting from the development of drug resistance to a par-
ticular antiretroviral agent. Founder envelope sequences have also been observed to co-evolve
with broadly neutralizing antibody [12, 46], which may indicate that initially susceptible fea-
tures in Env can be deduced from the covariance induced by the resulting mutational path-
ways. However all covariances within Env need not be related to changes due to immune
pressure so that the differences we determine between Founders and Chronics can encompass
aspects that will not be relevant to vaccine targets.
The covarying pairs link regions within Env. Linkage across domains, which is not surpris-
ing given the complex trimer structure which brings variable and conserved regions into close
proximity [22], is known to impact on infectivity and function [53, 54]. Some of the linkages
determined here may be due to the similar geographical regions from which the sequences
originated. Although chronic sequences were frequency-matched by geographical location,
this cannot be completely ruled out as contributing to some aspects of the optimal networks
determined here. The optimal pairs are likely components of more diverse networks that may
more precisely describe the multiple binding sites of any bNAbs or the mutational pathways
that the virus follows to evade them. The effects measured on gp41 AA beneath the membrane
could also arise from emergence of T cell responses. How these larger networks can be
extracted from this analysis is a more complex problem. It would also be beneficial to investi-
gate these in silico results in an in vitro setting.
In summary we have used operations research methods to determine the most prominent
features of Env that differ between founder and chronic sequences for subtype B and subtype
C. Our results suggest that the gut-homing α4β7 integrin plays a role in establishing infection
and may indicate key AAs desirable for inclusion in vaccine strains. Unlike subtype B where 9
AA pairs were in all optimal solutions, no single AA pair was present in all subtype C optimal
solutions (Table 3). This may highlight difficulties in targeting transmission with a single vac-
cine strain, especially for subtype C.
Materials and methods
Founder and chronic DNA sequences, as well as the HXB2 reference envelope sequence [55],
were converted to AA sequences (nt2aa, MATLAB 2012b, The MathWorks Inc., Natick MA,
USA), and then aligned using a progressive multiple alignment method (multialign). Pairwise
distances were calculated with the Jukes-Cantor method, with the phylogenetic tree generated
using the Unweighted Pair Group Method Average (seqlinkage). AA positions in the aligned
sequences were numbered relative to HXB2 according to the convention of Korber et al. [31].
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Pre-seroconverters
Env was sequenced from an additional set of subtype B virus for 5 newly infected males (esti-
mated 20 to 23 days from transmission, Fiebig Stage II (n = 4), and III (n = 1)) [56], where
transmission was through men having sex with men. Due to the cloning process only positions
44 to 752 of Env were sequenced from these transmission HIV strains.
These pre-seroconverter individuals were enrolled in a naturally history cohort study, the
Primary HIV and Early Disease Research: Australian Cohort (PHAEDRA), that was estab-
lished by the National Centre in HIV Epidemiology and Clinical Research to monitor immu-
nological and virological characteristics of individuals with acute and early HIV-1 infection.
Research ethics approval (number 02244) was given by St Vincent’s Hospital, Sydney,
Research Ethics Committee. All participants signed an informed consent form before study
entry.
Networks
The construction of a covariance network was previously described by Murray et al. [30], such
that the nodes of the network are given by each AA position, and each pair of covarying posi-
tions above the cut-off value provides an edge. Subtype B and C sequences were investigated
separately, along with three different sequence groups: i) all sequences within the subtype
(All), ii) the founder sequences and iii) the chronic sequences. As such, for a given subtype and
sequence group all covarying positions are contained in the set Psubtype,group. A network was
then constructed for each subtype and sequence group combination. We calculated optimal
networks based on each of these sets, extracting the “best” separating pairs (a separating pair is
defined as a covarying pair of positions and an AA combination present in at least one of the
founder sequences but in none of the chronic sequences), according to certain criteria and
where each founder sequence contained at least one of these separating pairs. The optimal sep-
aration of Founders from Chronics was performed using two criteria: i) separating with the
fewest pairs, and ii) using a weighting that simultaneously minimized the number of pairs and
maximized a measure of total covariance. The latter objective was achieved by applying the
weight wk = (Ŝ-Sk)2 to the cost of pair k, where Ŝ is the integer ceiling of the maximum of all
covariance values.
For these calculations we considered separating pairs for each AA combination so that opti-
mal solutions will extract single AA combinations at each pair of positions in the optimal net-
work [30].
As an example, the problem PB,All with optimal criterion (i) determines the smallest set of
AA combinations expressed by Founder sequences at covarying pairs where these were calcu-
lated on all subtype B sequences. In this instance, an optimal solution consists of the set of 13
pairs and AA described by {2–92 (Arg Lys), 24–293 (Ile Lys), 166–836 (Arg Thr), 178–535
(Asn Val), 232–236 (Thr Ser), 240–340 (Lys Lys), 279–315 (Asp Lys), 291–792 (Ala Ile), 322–
347 (Asp Thr), 535–620 (Lys Asp), 612–836 (Ala Lys), 724–837 (Arg Phe), 750–836 (Asp Ile)},
where each Founder sequence contains at least one (and possibly more) of these features,
while no Chronic sequence exhibits any of these features. In this way this set of AA pairs sepa-
rates all Founders from all Chronics. The optimality aspect guarantees that there are no other
combinations that separate the groups with fewer combinations, although there may be other
sets with the same number of pairs and hence are also optimal.
The binary integer programming method used to extract this smallest set from all separat-
ing pairs (formulated as described in Murray et al. [30]), is a standard optimization procedure,
where a variable xi is assigned to the ith separating pair and given the value 1 if it is included in
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the optimal set and value 0 otherwise. For this problem optimality is determined by allocating
the fewest 1 values among the xi.
Multiple optimal solutions for each subtype and group combination
These problems determining optimal separating pairs do not necessarily have unique solu-
tions. Multiple optimal solutions were identified using an iterative approach. Initially, the
problem was solved to identify an optimal solution. A constraint was then added to the prob-
lem to exclude the current solution. The problem was then resolved to identify another opti-
mal solution. For example, after calculating the optimal solution above, the separating pair
2–92 (Arg Lys) was excluded and the problem resolved. The solution to this restricted problem
also contained 13 pairs, and so comprised an additional optimal solution. On the other hand,
excluding 750–836 (Asp Ile) resulted in a solution requiring 14 pairs to separate the two groups
and so any optimal solution must include this combination.
Optimal solutions with no lower bound on covariance
The optimal solutions above were calculated over all pairs with a covariance value of at least
0.5. This implied that the pairs might exhibit some functional relationship between them oth-
erwise the AAs at these positions would more likely combine in a random manner. Different
cut-off values would allow more or fewer covarying pairs which would impact the optimal
solutions. To determine how much this could change we calculated optimal networks, only
using criterion (i) that minimized the number of pairs, over all pairs regardless of covariance.
The size of these problems, 177,906 subtype B pairs and 157,641 subtype C pairs, made calcu-
lating the optimal solution with criterion (ii), impractical for this NP Hard problem. As long
as we are not interested in generating connected networks where the AA match at the connect-
ing position [32], we can reduce the number of separating pairs by only including those that
are not dominated by others—a separating pair is said to be dominant if it is expressed by a set
of Founders IG and where there is no other separating pair which is expressed by Founders IG’
such that IG IG’., For example if the separating pair 180Ser-230Asn is exhibited by Founders
1, 2 and 3 while 130Ala-485Tyr is exhibited by Founders 1, 2, 3 and 5, then the first pair is
excluded from the calculations of separating Founders from Chronics with the fewest number
of pairs. The pair 130Ala-485Tyr dominates 180Ser-230Asn. After this calculation there are
only 1,358 dominant pairs for subtype B Founders and 928 dominant pairs for subtype C. The
binary integer programming method above can then be applied to this problem with no
covariance restriction.
All calculations were performed with Matlab version R2012b (The MathWorks Inc., Natick
MA, USA). The binary integer programming problems were solved using the bintprog routine
and the CPLEX toolbox (IBM, Armonk NY, USA).
Supporting information
S1 Table. Pairs of AA in optimal networks that separate Founders from Chronics. Each
item lists the pairs in the optimal network when calculations are performed over covariance
calculations determined on sequences in All, Founders or Chronics (Sep. Set). These are fea-
tures exhibited by some founder sequences but by no chronic sequence. The number of
sequences that exhibit that feature for that AA pair are listed as (n). Optimality was determined
either through choosing the fewest number of pairs (Prob = No) or through maximizing a
measure of total covariance (Prob = Yes).
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